CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Colesevelam Hydrochloride Tablets09-10-2019
09-10-2019
Cadila Healthcare Ltd - 532321 - Compliance Certificate For The Half Year Ended On September 30, 2019
Compliance Certificate for the half year ended on September 30, 201909-10-2019
Cadila Healthcare Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate08-10-2019
Cadila Healthcare Ltd - 532321 - Shareholding for the Period Ended September 30, 2019
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here08-10-2019
Cadila Healthcare Ltd - 532321 - Compliance Certificate For The Half Year Ended On September 30, 2019
Compliance Certificate for the half year ended on September 30, 201908-10-2019
CADILA HEALTHCARE LTD. - 532321 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0990 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer08-10-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces positive results from EVIDENCES IV Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD and NASH02-10-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Clobetasol Propionate Lotion.26-09-2019